

The Journal of Clinical Psychiatry

Subject Index to Volume 64: January 2003 Through December 2003

ACADEMIC HIGHLIGHTS

Determining and Achieving Therapeutic Targets in Attention-Deficit/Hyperactivity Disorder. Mar 265–276

New Developments in Antipsychotic Therapy. Nov 1379–1390

Reducing the Risk for Suicide in Schizophrenia and Affective Disorders. Sept 1122–1129

Adherence see Compliance

Adolescents

Childhood stimulant treatment and risk for later substance abuse. Fischer, Suppl 11, 19–23

Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. Gothelf, Oct 1163–1169

“Outer-directed irritability”: a distinct mood syndrome in explosive youth with a disruptive behavior disorder? Donovan, June 698–701

Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Biederman, Suppl 11, 3–8

Prolactin levels during long-term risperidone treatment in children and adolescents. Findling, Nov 1362–1369

Psychopathology and age at onset of conduct problems in juvenile delinquents. Ruchkin, Aug 913–920

Treatment of aggression in children and adolescents with autism and conduct disorder. McDougale, Suppl 4, 16–25

Affective Disorders

Ethnicity and diagnosis in patients with affective disorders. Strakowski, July 747–754

Reducing the Risk for Suicide in Schizophrenia and Affective Disorders [ACADEMIC HIGHLIGHTS]. Sept 1122–1129

Agitation

Agitation and inpatient suicide [letter]. Sharma V; Busch reply, Dec 1517–1518

Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. Brook, Suppl 19, 13–18

Randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Brodaty, Feb 134–143

Review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. Shale, May 500–505

Treatment of agitation in bipolar disorder across the life cycle. Alderfer, Suppl 4, 3–9

Aggression

Aggression in the elderly. Brodaty, Suppl 4, 36–43

Effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. Spivak, July 755–760

Hostility during admission interview as a short-term predictor of aggression in acute psychiatric male inpatients. Troisi, Dec 1460–1464

Impulsive aggressive behavior: open-label treatment with citalopram. Reist, Jan 81–85

Management of Aggression Across the Life Cycle. Suppl 4, 1–46

Neuroreceptor mechanisms of aggression and its treatment. Swann, Suppl 4, 26–35

Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. Janowsky, Oct 1258–1265

Randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Brodaty, Feb 134–143

Treating aggression in the psychiatric emergency service. Hughes, Suppl 4, 10–15

Treatment of aggression in children and adolescents with autism and conduct disorder. McDougale, Suppl 4, 16–25

Alcohol

Psychometric evaluation of the Alcohol Use Disorders Identification Test and short Drug Abuse Screening Test with psychiatric patients in India. Carey KB, July 767–774

Two cases of alcohol craving curbed by topiramate [letter]. Komanduri, May 612

Use of antidepressants in alcohol-dependent veterans. Petrakis, Aug 865–870

Algorithms

Computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. Oquendo, July 825–833

Role of algorithms in the detection and treatment of depression in primary care. Klinkman, Suppl 2, 19–23

Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. Suppes, Apr 370–382

Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. Rush, Apr 357–369

Use of algorithms to treat anxiety in primary care. Culpepper, Suppl 2, 30–33

Using treatment algorithms to bring patients to remission. Trivedi, Suppl 2, 8–13

Alzheimer's Disease

Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. Stahl, Apr 466–472

Current treatments for Alzheimer's disease: cholinesterase inhibitors. Doody, Suppl 9, 11–17

Diagnosis and treatment of Alzheimer's disease.

Grossberg, Suppl 9, 3–6

Neuropathologic changes in Alzheimer's disease. Wenk, Suppl 9, 7–10

Noncholinergic treatment options for Alzheimer's disease. Sano, Suppl 9, 23–28

Noncholinergic Treatments for Alzheimer's Disease. Suppl 9, 1–31

Search for better noncholinergic treatment options for Alzheimer's disease. Mintzer, Suppl 9, 18–22

Amitriptyline

Amitriptyline: dual-action antidepressant? [letter] Gillman; Thase reply, Nov 1391–1392

Analgesics

Analgesic effect of antidepressants [letter]. Fishbain; Detke reply, Jan 96–97

Anger

Anger in bipolar depression [letter]. Benazzi; Koh reply, Apr 480–481

Anticonvulsants see also specific drugs

Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. Evins, Suppl 8, 9–14

Emerging differential roles of GABAergic and ant glutamatergic agents in bipolar disorders. Ketter, Suppl 3, 15–20

Mechanism of action of newer anticonvulsants. White, Suppl 8, 5–8

Newer anticonvulsants: dosing strategies and cognition in treating patients with mood disorders and epilepsy. Meador, Suppl 8, 30–34

Antidepressants see also specific drugs

Analgesic effect of antidepressants [letter]. Fishbain; Detke reply, Jan 96–97

Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation. Labbate, Suppl 10, 11–19

Antidepressants and driver impairment: empirical evidence from a standard on-the-road test.

Ramaekers, Jan 20–29

Are antidepressants carcinogenic? a review of preclinical and clinical studies. Sternbach, Oct 1153–1162

Computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. Oquendo, July 825–833

Differences in mechanism of action between current and future antidepressants. Stahl, Suppl 13, 13–17

Do antidepressants induce rapid cycling? a gender-specific association. Yildiz, July 814–818

Effectiveness of antidepressants: comparative remission rates. Thase, Suppl 2, 3–7

Evaluating antidepressant therapies: remission as the optimal outcome. Thase, Suppl 13, 18–25

- How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? Keitner, Sept 1091–1093
- Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. DeVane, Suppl 18, 14–19
- Improving adherence to antidepressants: a systematic review of interventions. Vergouwen, Dec 1415–1420
- Improving antidepressant adherence. Nemeroff, Suppl 18, 25–30
- Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. Richelson, Suppl 13, 5–12
- Linezolid, a monoamine oxidase inhibiting antibiotic, and antidepressants [letter]. Aga, May 609–610
- Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. Corya, Nov 1349–1356
- Managing treatment-resistant major depression. Nelson, Suppl 1, 5–12
- New approaches in managing bipolar depression. Keck, Suppl 1, 13–18
- New approaches to managing psychotic depression. Schatzberg, Suppl 1, 19–23
- Possible antidepressant-associated activation of mania and psychosis in the mentally retarded: four case reports [letter]. Sahay, Apr 481–482
- Potential new drug delivery systems for antidepressants: an overview. Kilts, Suppl 18, 31–33
- Prevalence of antidepressant-associated erectile dysfunction. Rosen, Suppl 10, 5–10
- Sildenafil citrate for the management of antidepressant-associated erectile dysfunction. Nurnberg, Suppl 10, 20–25
- Three case reports of modafinil use in treating sedation induced by antipsychotic medications [letter]. Makela, Apr 485
- Use of antidepressants in alcohol-dependent veterans. Petrakis, Aug 865–870
- Use of antidepressants in novel combination therapies. Shelton, Suppl 2, 14–18
- Weight gain in breastfed infants of mothers taking antidepressant medications. Hendrick, Apr 410–412
- Antiemetic Drugs**
- Ups and downs of novel antiemetic drugs, pt 1: substance P, 5-HT, and the neuropharmacology of vomiting [BRAINSTORMS]. Stahl, May 498–499
- Ups and downs of novel antiemetic drugs, pt 2: an illustration [BRAINSTORMS]. Stahl, June 626–627
- Antipsychotics see also specific drugs**
- Chlorpromazine equivalent doses for the newer atypical antipsychotics. Woods, June 663–667
- Choice of maintenance medication for schizophrenia. Davis, Suppl 16, 24–33
- Combination therapy: is clinical practice leading the way? [letter] Welch; Stahl reply, Jan 94–96
- Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. Ereshefsky, Suppl 16, 18–23
- Conventional antipsychotic prescription in unipolar depression, 1: an audit and recommendations for practice. Wheeler Vega, May 568–574
- Conventional antipsychotic prescription in unipolar depression, 2: withdrawing conventional antipsychotics in unipolar, nonpsychotic patients. Mortimer, June 668–672
- Conventional, atypical, and combination antipsychotic prescriptions: a 2-year comparison. Tempier, June 673–679
- Cost and outcome implications of using typical and atypical antipsychotics in ordinary practice in Italy. Percudani, Nov 1293–1299
- Effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. Velligan, May 524–531
- Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia. Jaffe, Suppl 17, 3–6
- Efficacy of atypical antipsychotics in bipolar disorders. Hirschfeld, Suppl 8, 15–21
- Ethnic differences in use of antipsychotic medication among Texas Medicaid clients with schizophrenia. Opolka, June 635–639
- Factors influencing compliance in schizophrenia patients. Fleischhacker, Suppl 16, 10–13
- How long should patients with psychotic depression stay on the antipsychotic medication? Rothschild, Apr 390–396
- Integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. Carlson, Aug 898–906
- New approaches in managing bipolar depression. Keck, Suppl 1, 13–18
- New approaches to managing psychotic depression. Schatzberg, Suppl 1, 19–23
- New Developments in Antipsychotic Therapy [ACADEMIC HIGHLIGHTS]. Nov 1379–1390
- Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics [letter]. Haberfellner, July 851
- Optimizing Pharmacologic Treatment of Psychotic Disorders. Suppl 12, 1–100
- Overview of partial compliance. Marder, Suppl 16, 3–9
- Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. Taylor, Jan 30–34
- Racial differences in use of antipsychotics among patients with bipolar disorder [letter]. Szarek; Fleck reply, May 614–615
- Relapse and rehospitalization: comparing oral and depot antipsychotics. Schooler, Suppl 16, 14–17
- Reversal of antipsychotic-associated weight gain. O'Keefe, Aug 907–912
- Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Atmaca, May 598–604
- Similarities and differences among antipsychotics. Tamminga, Suppl 17, 7–10
- Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Kane, Suppl 16, 34–40
- Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. Godleski, Feb 119–122
- Three case reports of modafinil use in treating sedation induced by antipsychotic medications [letter]. Makela, Apr 485–486
- Use of atypical antipsychotics in nursing homes. Liperoti, Sept 1106–1112
- Anxiety**
- Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. Henry, Mar 331–335
- Anxiety symptoms and quality of life in middle-aged and older outpatients with schizophrenia and schizoaffective disorder. Wetherell, Dec 1476–1482
- Attending to anxiety disorders in primary care. Stein, Suppl 15, 35–39
- Establishment of remission criteria for anxiety disorders. Doyle, Suppl 15, 40–45
- Introduction: treating depression and anxiety to remission. Schatzberg, Suppl 15, 3–4
- New molecular targets for antianxiety interventions. Gorman, Suppl 3, 28–35
- Nonhuman primate studies of fear, anxiety, and temperament and the role of benzodiazepine receptors and GABA systems. Kalin, Suppl 3, 41–44
- Role of GABA in anxiety disorders. Lydiard, Suppl 3, 21–27
- Treatment of anxiety in suicidal patients [letter]. Rich; Fawcett reply, Dec 1518–1519
- Use of algorithms to treat anxiety in primary care. Culpepper, Suppl 2, 30–33
- Anxiolytics**
- Anxiolytics: past, present, and future agents. Nemeroff, Suppl 3, 3–6
- Emerging differential roles of GABAergic and antiserotonergic agents in bipolar disorders. Ketter, Suppl 3, 15–20
- New molecular targets for antianxiety interventions. Gorman, Suppl 3, 28–35
- Aripiprazole**
- Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. Pigott, Sept 1048–1056
- Attention-Deficit/Hyperactivity Disorder**
- Childhood stimulant treatment and risk for later substance abuse. Fischer, Suppl 11, 19–23
- Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. Kollins, Suppl 11, 14–18
- Determining and Achieving Therapeutic Targets in Attention-Deficit/Hyperactivity Disorder [ACADEMIC HIGHLIGHTS]. Mar 265–276
- Does stimulant treatment lead to substance use disorders? Faraone, Suppl 11, 9–13
- Long-Term Safety of Methylphenidate in the Treatment of ADHD: Dispelling the Myths and Misconceptions About Stimulant Therapy Abuse. Suppl 11, 1–26
- Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. Gothelf, Oct 1163–1169

- Occult mood disorders in 104 consecutively presenting children referred for the treatment of attention-deficit/hyperactivity disorder in a community mental health clinic. Dilsaver, Oct 1170–1176
- Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Biederman, Suppl 11, 3–8
- Role of executive function in ADHD. Swanson, Suppl 14, 35–39
- Australia**
- Posttraumatic stress disorder and its impact on the economic and health costs of motor vehicle accidents in South Australia. Chan, Feb 175–181
- Autism**
- Evidence that eicosapentaenoic acid is effective in treating autism [letter]. Johnson, July 848–849
- Treatment of aggression in children and adolescents with autism and conduct disorder. McDougle, Suppl 4, 16–25
- Automobile Driving**
- Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. Ramaekers, Jan 20–29
- Posttraumatic stress disorder and its impact on the economic and health costs of motor vehicle accidents in South Australia. Chan, Feb 175–181
- Baclofen**
- Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. Shoptaw, Dec 1440–1448
- Basal Ganglia**
- Possible basal ganglia pathology in children with complex symptoms. Yaryura-Tobias, Dec 1495–1501
- Behavior**
- Double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. Fontaine, June 726–730
- Evaluating the efficacy of habit reversal: comparison with a placebo control. Twohig, Jan 40–48
- Impulsive aggressive behavior: open-label treatment with citalopram. Reist, Jan 81–85
- “Outer-directed irritability”: a distinct mood syndrome in explosive youth with a disruptive behavior disorder? Donovan, June 698–701
- Possible basal ganglia pathology in children with complex symptoms. Yaryura-Tobias, Dec 1495–1501
- Benzodiazepines**
- GABA systems, benzodiazepines, and substance dependence. Malcolm, Suppl 3, 36–40
- Benzodiazepine Receptors**
- Nonhuman primate studies of fear, anxiety, and temperament and the role of benzodiazepine receptors and GABA systems. Kalin, Suppl 3, 41–44
- Binge-Eating Disorder**
- Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. McElroy, July 807–813
- Bipolar Disorders**
- Achieving Success in the Management of Bipolar Disorder: Is Lithium Sufficient? Suppl 5, 1–64
- Anger in bipolar depression [letter]. Benazzi; Koh reply, Apr 480–481
- Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. Henry, Mar 331–335
- Bipolar disorder and schizophrenia: distinct illnesses or a continuum? Möller, Suppl 6, 23–27
- Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. Keck, Dec 1426–1435
- Bipolar Disorder: Origin, Recognition, and Treatment. Suppl 6, 1–28
- Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. Ciapparelli, Apr 451–458
- Conclusions. Bipolar disorder: origin, recognition, and treatment. Rush, Suppl 6, 28
- Decision tree for the treatment of bipolar disorder. Sachs, Suppl 8, 35–40
- Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. Chang KD, Aug 936–942
- Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. Revicki, Mar 288–294
- Drug combinations for mania. Mondimore, Suppl 5, 25–31
- Drug interactions of lithium and other antimanic/mood-stabilizing medications. Dunner, Suppl 5, 38–43
- Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis. Birnbaum HG, Oct 1201–1209
- Efficacy of atypical antipsychotics in bipolar disorders. Hirschfeld, Suppl 8, 15–21
- Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. Evins, Suppl 8, 9–14
- Emerging differential roles of GABAergic and antilglutamatergic agents in bipolar disorders. Ketter, Suppl 3, 15–20
- Estrogen administration does not reduce the rate of recurrence of affective psychosis after childbirth. Kumar, Feb 112–118
- Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. Leverich, May 506–515
- Impact of bipolar disorder on a U.S. community sample. Calabrese, Apr 425–432
- Integrated family and individual therapy for bipolar disorder: results of a treatment development study. Miklowitz, Feb 182–191
- Introduction. Bipolar disorder: origin, recognition, and treatment. Rush, Suppl 6, 3
- Introduction: Using the newer pharmacotherapeutic agents as mood stabilizers in bipolar spectrum disorders. Chengappa, Suppl 8, 3–4
- Lamotrigine in patients with bipolar disorder and cocaine dependence. Brown ES, Feb 197–201
- Lithium combinations in acute and maintenance treatment of unipolar and bipolar depression. Fawcett, Suppl 5, 32–37
- Lithium treatment and suicide risk in major affective disorders: update and new findings. Baldessarini, Suppl 5, 44–52
- Maudsley Bipolar Disorder Project: the effect of medication, family history, and duration of illness on IQ and memory in bipolar I disorder. Donaldson, Jan 86–93
- Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH Life Chart Method. Post, June 680–690
- New approaches in managing bipolar depression. Keck, Suppl 1, 13–18
- Newer anticonvulsants: dosing strategies and cognition in treating patients with mood disorders and epilepsy. Meador, Suppl 8, 30–34
- Nutritional approach to bipolar disorder [letter]. Simmons; Simpson reply, Mar 338–339
- Oxcarbazepine treatment of bipolar disorder. Ghaemi, Aug 943–945
- Perceptions and impact of bipolar disorder: how far have we really come? results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. Hirschfeld, Feb 161–174
- Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Calabrese, Sept 1013–1024
- Prophylactic efficacy of lithium versus carbamazepine in treatment-naïve bipolar patients. Hartong, Feb 144–151
- Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. Colom, Sept 1101–1105
- Racial differences in use of antipsychotics among patients with bipolar disorder [letter]. Szarek; Fleck reply, May 614–615
- Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. Kupka, Dec 1483–1494
- Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. Goodwin, Suppl 5, 18–24
- Relationship between postpartum psychosis and bipolar disorder: a review. Chaudron, Nov 1284–1292
- Response, remission, and recovery in bipolar disorder: what are the realistic treatment goals? Sachs, Suppl 6, 18–22
- Safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. Hirschfeld, July 841–846
- Safety of available agents used to treat bipolar disorder: focus on weight gain. Nemeroff, May 532–539
- Screening for bipolar disorder in the community. Hirschfeld, Jan 53–59
- Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. Grof, Suppl 5, 53–61
- Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. Suppes, Apr 370–382
- Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. Rush, Apr 357–369

- Toward an understanding of bipolar disorder and its origin. Rush, Suppl 6, 4–8
- Treatment of agitation in bipolar disorder across the life cycle. Alderfer, Suppl 4, 3–9
- Treatment of bipolar disorder. Möller, Suppl 6, 9–17
- Underdiagnosis of bipolar II disorders in the community [letter]. Benazzi, Sept 1130–1131
- Using the Newer Pharmacotherapeutic Agents as Mood Stabilizers in Bipolar Spectrum Disorders. Suppl 8, 1–40
- Weight gain in the treatment of mood disorders. Aronne, Suppl 8, 22–29

Bleeding

- Critical review of selective serotonin reuptake inhibitor–associated bleeding: balancing the risk of treating hepatitis C–infected patients. Weinrieb, Dec 1502–1510

Body Dysmorphic Disorder

- Open-label study of citalopram in body dysmorphic disorder. Phillips, June 715–720

Bone

- Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. Becker D, July 761–766

Books Reviewed

- Arciniegas DB, Beresford TP: *Neuropsychiatry: An Introductory Approach*. Rao, May 616–617
- Barlow DH: *Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic, 2nd ed*. Prakash, Mar 345–346
- Bennett MI: *Concise Guide to Managing Behavioral Health Care Within a Managed Care Environment*. Strain, Nov 1398
- Berrios GE, Hodges JR (eds): *Memory Disorders in Psychiatric Practice*. Miller MG, June 736–737
- Birren JE, Schaie KW (eds): *Handbook of the Psychology of Aging, 5th ed*. Casten, Feb 221
- Chan CH, Luo JS, Kennedy RS: *Concise Guide to Computers in Clinical Psychiatry*. Kramer, Apr 487–488
- Committee on Cultural Psychiatry: *Cultural Assessment in Clinical Psychiatry (GAP Report 145)*. Kopelowicz, Mar 344
- Csernansky JG (ed): *Schizophrenia: A New Guide for Clinicians*. Lee, Apr 489
- Dickey B, Sederer LI (eds): *Improving Mental Health Care: Commitment to Quality*. Bennett, Apr 488–489
- Ernst M, Rumsey JM (eds): *Functional Neuroimaging in Child Psychiatry*. Mrazek, Jan 102
- Gelder M, Mayou R, Cowen P: *Shorter Oxford Textbook of Psychiatry, 4th ed*. Gershon, Jan 100–101
- González FJ (ed): *HIV and Depression: Context and Care (UCSF AIDS Health Project Monograph Series, No. 5)*. Hargrave, Feb 221–222
- Gotlib IH, Hammen CL (eds): *Handbook of Depression*. Schnaas, Dec 1523–1524
- Griez EJJ, Faravelli C, Nutt D, Zohar J (eds): *Anxiety Disorders: An Introduction to Clinical Management and Research*. Brown LL, Jan 100
- Gualtieri CT: *Brain Injury and Mental Retardation: Psychopharmacology and Neuropsychiatry*. Benjamin, Dec 1522–1523
- Gutheil TG, Simon RI: *Mastering Forensic Psychiatric Practice: Advanced Strategies for the Expert Witness*. Alonso, Aug 973
- Helzer JE, Hudziak JJ (eds): *Defining Psychopathology in the 21st Century: DSM-V and Beyond*. Salomon, Nov 1399
- Herz MI, Marder SR: *Schizophrenia: Comprehensive Treatment and Management*. Siris, Mar 345
- Hodges JR (ed): *Early-Onset Dementia: A Multidisciplinary Approach*. Kirshner, Nov 1396
- Hofmann SG, Thompson MC (eds): *Treating Chronic and Severe Mental Disorders: A Handbook of Empirically Supported Interventions*. Ronis, Dec 1524
- Hollander E: *Concise Guide to Anxiety Disorders*. Straumanis, Nov 1396–1397
- Horowitz MJ: *Treatment of Stress Response Syndromes*. Vaillant, Oct 1272–1273
- Howlin P, Udwin O (eds): *Outcomes in Neurodevelopmental and Genetic Disorders*. Matthews, Sept 1136
- Jacobson SA, Pies RW, Greenblatt DJ: *Handbook of Geriatric Psychopharmacology*. Wahid, Jan 101
- Kaplan GB, Hammer RP Jr (eds): *Brain Circuitry and Signaling in Psychiatry: Basic Science and Clinical Implications*. Salomon, June 737
- Kupfer DJ, First MB, Regier DA (eds): *A Research Agenda for DSM-IV*. McKinney, Dec 1522
- Lieberman JA, Murray R (eds): *Comprehensive Care of Schizophrenia: A Textbook of Clinical Management*. Herz, Apr 490
- Marangell LB, Martinez JM, Silver JM, Yudofsky SC: *Concise Guide to Psychopharmacology*. Roerig, Nov 1397–1398
- Martin A, Scahill L, Charney DS, Leckman JF (eds): *Pediatric Psychopharmacology: Principles and Practice*. Sexson, Aug 974
- Melmed RN: *Mind, Body, and Medicine: An Integrative Text*. Strauss, Jan 101–102
- Meyers WC: *Juvenile Sexual Homicide*. Bernet, Apr 487
- Mondimore FM: *Adolescent Depression: A Guide for Parents*. Slomowitz, July 855
- Paris J: *Personality Disorders Over Time: Precursors, Course, and Outcome*. Lomax, Oct 1271
- Peebles-Kleiger MJ: *Beginnings: The Art and Science of Planning Psychotherapy*. Nash, June 736
- Phillips KA (ed): *Somatoform and Factitious Disorders*. Sudak, Jan 99–100
- Robinson DJ: *Brain Calipers, 2nd ed: Descriptive Psychopathology and the Psychiatric Mental Status Examination*. Crowder, Apr 489–490
- Rogers R: *Handbook of Diagnostic and Structured Interviewing*. Reus, Apr 488
- Scheiber SC, Kramer TAM, Adamowski SE (eds): *Core Competencies for Psychiatric Practice: What Clinicians Need to Know (A Report of the American Board of Psychiatry and Neurology)*. Weissman, Sept 1135
- Shader RI (ed): *Manual of Psychiatric Therapeutics, 3rd ed*. Freeman, Oct 1272
- Simon RI, Shuman DW (eds): *Retrospective Assessment of Mental States in Litigation: Predicting the Past*. Regan, Oct 1271–1272

- Spinelli MG (ed): *Infanticide: Psychosocial and Legal Perspectives on Mothers Who Kill*. Caruso, Sept 1135–1136
- Stahl SM: *Essential Psychopharmacology of Antipsychotics and Mood Stabilizers*. Salzman, Aug 973–974
- Stein DJ, Hollander E (eds): *American Psychiatric Publishing Textbook of Anxiety Disorders*. Appleton, May 617–618
- Theorell T (ed): *Everyday Biological Stress Mechanisms*. Straumanis, Mar 344–345
- Yehuda R (ed): *Treating Trauma Survivors With PTSD*. Roback, May 617

Brain

- Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. Stahl, Suppl 14, 6–17
- Enlargement of brain cerebrospinal fluid spaces as a predictor of poor clinical outcome in melancholia. Cardoner, June 691–697
- Long-term follow-up of magnetic resonance–detectable choline signal changes in the hippocampus of patients treated with electroconvulsive therapy. Obergriesser, July 775–780

Brain Imaging

- Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy. Weiss, Mar 235–242
- Efficacy and safety of bilateral rTMS in medication-resistant depression [letter]. Cohen, May 613–614
- Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders. Chang, Suppl 3, 7–14

BRAINSTORMS

- Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes. Stahl, July 745–746
- At long last, long-lasting psychiatric medications: an overview of controlled-release technologies. Stahl, Apr 355–356
- Deconstructing psychiatric disorders, pt 1: genotypes, symptom phenotypes, and endophenotypes. Stahl, Sept 982–983
- Deconstructing psychiatric disorders, pt 2: an emerging, neurobiologically based therapeutic strategy for the modern psychopharmacologist. Stahl, Oct 1145–1146
- Here today and not gone tomorrow: the curse of chronic pain and other central sensitization syndromes. Stahl, Aug 863–864
- Neurotransmission of cognition, pt 1. Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine. Stahl, Jan 4–5
- Neurotransmission of cognition, pt 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. Stahl, Feb 110–111
- Neurotransmission of cognition, pt 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex. Stahl, Mar 230–231
- Symptoms and circuits, pt 1: major depressive disorder. Stahl, Nov 1282–1283

- Symptoms and circuits, pt 2: anxiety disorders. Stahl, Dec 1408–1409
- Ups and downs of novel antiemetic drugs, pt 1: substance P, 5-HT, and the neuropharmacology of vomiting. Stahl, May 498–499
- Ups and downs of novel antiemetic drugs, pt 2: an illustration. Stahl, June 626–627
- Breastfeeding**
- Pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. Stowe, Jan 73–80
- Safety of St. John's Wort (*Hypericum perforatum*) during breastfeeding. Lee A, Aug 966–968
- Weight gain in breastfed infants of mothers taking antidepressant medications. Hendrick, Apr 410–412
- Bulimia Nervosa**
- Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, pt 1: improvement in binge and purge measures. Hoopes, Nov 1335–1341
- Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, pt 2: improvement in psychiatric measures. Hedges, Dec 1449–1454
- Bupropion**
- Effect of bupropion on sexual dysfunction induced by fluoxetine: a case report of hypersexuality [letter]. Chollet, Oct 1268–1269
- They could have named it "bupopion" [letter]. Jefferson, July 849–850
- Burning Mouth Syndrome**
- Burning mouth syndrome as a side effect of SSRIs [letter]. Levenson; Maina reply, Mar 336–338
- Carbamazepine**
- Carbamazepine treatment of adverse psychiatric effects after treatment with the nonsteroidal anti-inflammatory drug piroxicam [letter]. Eser, July 852–854
- Prophylactic efficacy of lithium versus carbamazepine in treatment-naïve bipolar patients. Hartong, Feb 144–151
- Carcinogenesis**
- Are antidepressants carcinogenic? a review of preclinical and clinical studies. Sternbach, Oct 1153–1162
- Celecoxib**
- Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. Phelan, Nov 1328–1334
- Charles Bonnet Syndrome**
- Charles Bonnet Syndrome with visual hallucinations of childhood experience: successful treatment of 1 patient with risperidone [letter]. Maeda, Sept 1131–1132
- Children**
- Childhood stimulant treatment and risk for later substance abuse. Fischer, Suppl 11, 19–23
- Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. Gothelf, Oct 1163–1169
- Occult mood disorders in 104 consecutively presenting children referred for the treatment of attention-deficit/hyperactivity disorder in a community mental health clinic. Dilsaver, Oct 1170–1176
- "Outer-directed irritability": a distinct mood syndrome in explosive youth with a disruptive behavior disorder? Donovan, June 698–701
- Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Biederman, Suppl 11, 3–8
- Physical symptoms of depression: unmet needs in special populations. Stewart, Suppl 7, 12–16
- Possible basal ganglia pathology in children with complex symptoms. Yaryura-Tobias, Dec 1495–1501
- Prolactin levels during long-term risperidone treatment in children and adolescents. Findling, Nov 1362–1369
- 3-Year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. Masi, Sept 1039–1047
- Treatment of aggression in children and adolescents with autism and conduct disorder. McDougle, Suppl 4, 16–25
- Chinese**
- Double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. Hong, Aug 921–926
- Cholesterol**
- Increased cholesterol levels during paroxetine administration in healthy men. Lara, Dec 1455–1459
- Cholinesterase Inhibitors**
- Current treatments for Alzheimer's disease: cholinesterase inhibitors. Doody, Suppl 9, 11–17
- Cigarette Smoking**
- High-frequency repetitive transcranial magnetic stimulation decreases cigarette smoking. Eichhammer, Aug 951–953
- Citalopram**
- Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. Koran, July 793–798
- Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. McElroy, July 807–813
- Citalopram treatment of fluoxetine-intolerant depressed patients. Calabrese, May 562–567
- Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. Lavretsky, Dec 1410–1414
- Effectiveness of citalopram for idiopathic chronic fatigue. Hartz, Aug 927–935
- Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. Soares, Apr 473–479
- Impulsive aggressive behavior: open-label treatment with citalopram. Reist, Jan 81–85
- Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. Benedetti, June 648–653
- Open-label study of citalopram in body dysmorphic disorder. Phillips, June 715–720
- Clinical Trials**
- How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? Keitner, Sept 1091–1093
- Clozapine**
- Clozapine and pregnancy [letter]. Mendhekar, July 850
- Clozapine and venous thromboembolism: further evidence [letter]. Seltin, May 609
- Clozapine-induced rabbit syndrome [letter]. Sethi, Feb 219
- Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. Ciapparelli, Apr 451–458
- Effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. Spivak, July 755–760
- Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. Taylor, Jan 30–34
- Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine [letter]. Kelly DL, Sept 1133–1134
- Successful treatment with clozapine at higher doses after clozapine-induced priapism [letter]. de Nesnera, Nov 1394–1395
- Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. Sernyak, May 605–608
- Ziprasidone augmentation of clozapine in 11 patients [letter]. Kaye, Feb 215–216
- Cocaine**
- Olanzapine for cocaine cravings and relapse prevention [letter]. Sattar, Aug 969
- Lamotrigine in patients with bipolar disorder and cocaine dependence. Brown ES, Feb 197–201
- Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. Shoptaw, Dec 1440–1448
- Cognition**
- Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy. Weiss, Mar 235–242
- Effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. Velligan, May 524–531
- Neurotransmission of cognition, pt 1. Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine [BRAINSTORMS]. Stahl, Jan 4–5
- Neurotransmission of cognition, pt 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition [BRAINSTORMS]. Stahl, Feb 110–111
- Neurotransmission of cognition, pt 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex [BRAINSTORMS]. Stahl, Mar 230–231
- Ziprasidone and cognition: the evolving story. Harvey, Suppl 19, 33–39
- Cognitive Therapy**
- Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. Kennedy, Apr 439–444

Cohen-Mansfield Agitation Inventory

Reporting changes in scores on the Cohen-Mansfield Agitation Inventory subscales [letter]. Snowdon; Ballard reply, June 732

Combination Therapy

Combination therapy: is clinical practice leading the way? [letter] Welch; Stahl reply, Jan 94–96
 Drug combinations for mania. Mondimore, Suppl 5, 25–31
 Drug interactions of lithium and other antimanic/mood-stabilizing medications. Dunner, Suppl 5, 38–43
 Lithium combinations in acute and maintenance treatment of unipolar and bipolar depression. Fawcett, Suppl 5, 32–37
 Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. Goodwin, Suppl 5, 18–24
 Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. Grof, Suppl 5, 53–61
 Use of antidepressants in novel combination therapies [commentary]. Shelton, Suppl 2, 14–18

Comorbidity

Chronic depression and comorbid personality disorders: response to sertraline versus imipramine. Russell, May 554–561
 Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. Papakostas, Nov 1357–1361

Compliance

Factors influencing compliance in schizophrenia patients. Fleischhacker, Suppl 16, 10–13
 Improving adherence to antidepressants: a systematic review of interventions. Vergouwen, Dec 1415–1420
 Improving antidepressant adherence. Nemeroff, Suppl 18, 25–30
 Overview of partial compliance. Marder, Suppl 16, 3–9
 Partial compliance and patient consequences in schizophrenia: our patients can do better. Keith, Nov 1308–1315
 Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Kane, Suppl 16, 34–40

Compulsive Shopping Disorder

Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. Koran, July 793–798
 1-Year naturalistic follow-up of patients with compulsive shopping disorder. Aboujaoude, Aug 946–950

Conduct Disorder

Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. Steiner, Oct 1183–1191
 Psychopathology and age at onset of conduct problems in juvenile delinquents. Ruchkin, Aug 913–920
 Treatment of aggression in children and adolescents with autism and conduct disorder. McDougle, Suppl 4, 16–25

Consensus Statements

Optimizing Pharmacologic Treatment of Psychotic Disorders. Suppl 12, 1–100

Controlled-Release Technologies

At long last, long-lasting psychiatric medications: an overview of controlled-release technologies [BRAINSTORMS]. Stahl, Apr 355–356
 Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. DeVane, Suppl 18, 14–19

Corrections

Oral magnesium ion shortens prolonged QTc interval [letter]. Bachman, June 733–734. Correction, Aug 972
 Venlafaxine in treatment-resistant obsessive-compulsive disorder. Hollander E, May 546–550. Correction, Aug 972

Costs of Medical Care see also**Pharmacoeconomics**

Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder. Endicott, Dec 1511–1516
 Cost and outcome implications of using typical and atypical antipsychotics in ordinary practice in Italy. Percudani, Nov 1293–1299
 Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. Revicki, Mar 288–294
 Economic and human impact of new drugs. Lichtenberg, Suppl 17, 15–18
 Economic burden of depression in the United States: how did it change between 1990 and 2000? Greenberg, Dec 1465–1475
 Economic burden of depression with painful symptoms. Greenberg, Suppl 7, 17–23
 Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis. Birnbaum HG, Oct 1201–1209
 Limiting access to psychiatric services can increase total health care costs. Horn, Suppl 17, 23–28
 Posttraumatic stress disorder and its impact on the economic and health costs of motor vehicle accidents in South Australia. Chan, Feb 175–181
 Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. Taylor, May 589–597
 Unintended outcomes of Medicaid drug cost-containment policies on the chronically mentally ill. Soumerai, Suppl 17, 19–22

Creatine Kinase

Olanzapine elevation of serum creatine kinase [letter]. Martí-Bonmatí, Apr 483–484

Delirium

Prospective, open-label, flexible-dose study of quetiapine in the treatment of delirium. Sasaki, Nov 1316–1321

Dementia

Double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. Fontaine, June 726–730
 Randomized controlled trial of different models of care for nursing home residents with dementia complicated by depression or psychosis. Brodaty, Jan 63–72
 Randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Brodaty, Feb 134–143

Two cases of quetiapine augmentation for donepezil-refractory visual hallucinations in dementia with Lewy bodies [letter]. Terao, Dec 1520–1521

Depersonalization Disorder

Feeling unreal: a depersonalization disorder update of 117 cases. Simeon, Sept 990–997

Depression

Achieving remission and managing relapse in depression. Thase, Suppl 18, 3–7
 Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. DeBattista, Sept 1057–1064
 Aerobic endurance exercise improves executive functions in depressed patients. Kubesch, Sept 1005–1012
 Aging male: androgens, erectile dysfunction, and depression. Seidman, Suppl 10, 31–37
 Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. Stahl, Suppl 14, 6–17
 Can long-term treatment with antidepressant drugs worsen the course of depression? Fava GA, Feb 123–133
 Chronic depression and comorbid personality disorders: response to sertraline versus imipramine. Russell, May 554–561
 Citalopram treatment of fluoxetine-intolerant depressed patients. Calabrese, May 562–567
 Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. Winokur, Oct 1224–1229
 Computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. Oquendo, July 825–833
 Conventional antipsychotic prescription in unipolar depression, 1: an audit and recommendations for practice. Wheeler Vega, May 568–574
 Conventional antipsychotic prescription in unipolar depression, 2: withdrawing conventional antipsychotics in unipolar, nonpsychotic patients. Mortimer, June 668–672
 Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. Mallick, Mar 321–330
 Depression: links with ischemic heart disease and erectile dysfunction. Roose, Suppl 10, 26–30
 Depression with physical symptoms: treating to remission. Fava, Suppl 7, 24–28
 Difficult-to-treat depressions: a primary care perspective. Manning, Suppl 1, 24–31
 Double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. Amsterdam, Feb 208–214
 Double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. Hong, Aug 921–926

- Double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Barbosa, Apr 403–407
- Duloxetine in the long-term treatment of major depressive disorder. Raskin, Oct 1237–1244
- Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. Szegedi, Apr 413–420
- Economic burden of depression in the United States: how did it change between 1990 and 2000? Greenberg, Dec 1465–1475
- Economic burden of depression with painful symptoms. Greenberg, Suppl 7, 17–23
- Efficacy and safety of bilateral rTMS in medication-resistant depression [letter]. Cohen, May 613–614
- Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. Schatzberg, Suppl 13, 30–37
- Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. Soares, Apr 473–479
- Efficacy of controlled-release paroxetine in the treatment of late-life depression. Rapaport, Sept 1065–1074
- Electroconvulsive therapy update: recognizing and treating psychotic depression [editorial]. Fink, Mar 232–234
- Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report [letter]. Detweiler, July 851–852
- Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. Feiger, Mar 243–249
- How long should patients with psychotic depression stay on the antipsychotic medication? Rothschild, Apr 390–396
- How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? Keitner, Sept 1091–1093
- Introduction: erectile dysfunction and comorbid depression: prevalence, treatment strategies, and associated medical conditions. Nurnberg, Suppl 10, 3–4
- Introduction: recent developments in achieving depression remission. Schatzberg, Suppl 13, 4
- Introduction: treating depression and anxiety to remission. Schatzberg, Suppl 15, 3–4
- Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. Kennedy, Apr 439–444
- Lithium combinations in acute and maintenance treatment of unipolar and bipolar depression. Fawcett, Suppl 5, 32–37
- Lithium treatment and suicide risk in major affective disorders: update and new findings. Baldessarini, Suppl 5, 44–52
- Managing treatment-resistant major depression. Nelson, Suppl 1, 5–12
- Negative symptoms in depressed and schizophrenic patients: how do they differ? Bottlender, Aug 954–958
- New Approaches to Managing Difficult-to-Treat Depressions. Suppl 1, 1–34
- New approaches to managing difficult-to-treat depressions. Thase, Suppl 1, 3–4
- New approaches to managing psychotic depression. Schatzberg, Suppl 1, 19–23
- Nortriptyline for treatment-resistant depression. Nierenberg, Jan 35–39
- Open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder. Carvalhal, Apr 421–424
- Physical Symptoms of Depression and Their Impact on Patients and Society. Suppl 7, 1–31
- Physical symptoms of depression as a public health concern. Sartorius, Suppl 7, 3–4
- Physical symptoms of depression: unmet needs. Greden, Suppl 7, 5–11
- Physical symptoms of depression: unmet needs in special populations. Stewart, Suppl 7, 12–16
- Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. Nierenberg, Suppl 15, 13–17
- Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. Papakostas, Nov 1357–1361
- Randomized controlled trial of different models of care for nursing home residents with dementia complicated by depression or psychosis. Brodaty, Jan 63–72
- Relationship of personality disorders to treatment outcome in depressed outpatients. Mulder, Mar 259–264
- Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice. Cuffel, Apr 397–402
- Residual symptoms in depression: can treatment be symptom-specific? Menza, May 516–523
- Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. Sharpley, Feb 192–196
- Role of algorithms in the detection and treatment of depression in primary care. Klinkman, Suppl 2, 19–23
- Role of executive function in late-life depression. Alexopoulos, Suppl 14, 18–23
- Role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. Fava M, Suppl 13, 26–29
- Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression. Simpson, Aug 959–965
- Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. Lepola, June 654–662
- Special issues related to the treatment of depression in women. Yonkers, Suppl 18, 8–13
- Suicidal ideation and attempts among psychiatric patients with major depressive disorder. Sokero, Sept 1094–1100
- Symptoms and circuits, pt 1: major depressive disorder [BRAINSTORMS]. Stahl, Nov 1282–1283
- Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. Fava M, Suppl 14, 30–34
- Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. Rush, Apr 357–369
- Treating Depression and Anxiety to Remission: Use of Algorithms. Suppl 2, 1–36
- Treating Depression: New Choices for a Chronic Problem. Suppl 18, 1–36
- Treating depression to remission. Zajecka, Suppl 15, 7–12
- Treatment of leuprolide-induced depression with intramuscular testosterone: a case report [letter]. Freeman, Mar 341–343
- Treatment strategies for sleep disturbance in patients with depression. Doghramji, Suppl 14, 24–29
- Dermatology**
- How common is obsessive-compulsive disorder in a dermatology outpatient clinic? Fineberg, Feb 152–155
- Developmental Disorders**
- 3-Year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. Masi, Sept 1039–1047
- Treatment of previously undiagnosed psychiatric disorders in persons with developmental disabilities decreased or eliminated self-injurious behavior. Tsiouris, Sept 1081–1090
- Diabetes**
- Olanzapine/risperidone and diabetes risk [letter]. Lee; Gianfrancesco reply, July 847–848
- Diet**
- Double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. Amsterdam, Feb 208–214
- Disability**
- Sexual satisfaction and risk of disability in older women. Onder, Oct 1177–1182
- Divalproex Sodium**
- Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. Chang KD, Aug 936–942
- Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. Steiner, Oct 1183–1191
- Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. Revicki, Mar 288–294
- Divalproex versus olanzapine in mania [letter]. Vieta; Zajecka reply, Oct 1266–1267
- Safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. Hirschfeld, July 841–846
- Donepezil**
- Can donepezil be considered a mild antipsychotic in dementia treatment? a report of donepezil use in 6 patients [letter]. Terao, Nov 1392–1393
- Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. Stahl, Apr 466–472
- Two cases of quetiapine augmentation for donepezil-refractory visual hallucinations in dementia with Lewy bodies [letter]. Terao, Dec 1520–1521

Dosage

Chlorpromazine equivalent doses for the newer atypical antipsychotics. Woods, June 663–667
 Newer anticonvulsants: dosing strategies and cognition in treating patients with mood disorders and epilepsy. Meador, Suppl 8, 30–34

Droperidol

Review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. Shale, May 500–505

Drug Abuse

Psychometric evaluation of the Alcohol Use Disorders Identification Test and short Drug Abuse Screening Test with psychiatric patients in India. Carey KB, July 767–774

Drug Administration

Can long-term treatment with antidepressant drugs worsen the course of depression? Fava GM, Feb 123–133

Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. Ereshefsky, Suppl 16, 18–23

Double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. Amsterdam, Feb 208–214

Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. DeVane, Suppl 18, 14–19

Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. Brook, Suppl 19, 13–18

Potential new drug delivery systems for antidepressants: an overview. Kilts, Suppl 18, 31–33

Relapse and rehospitalization: comparing oral and depot antipsychotics. Schooler, Suppl 16, 14–17

Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Kane, Suppl 16, 34–40

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Fleischacker, Oct 1250–1257

Duloxetine

Duloxetine in the long-term treatment of major depressive disorder. Raskin, Oct 1237–1244

Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. Schatzberg, Suppl 13, 30–37

Word of caution about the implied role for duloxetine in pain management [letter]. Leo, Oct 1270

Economics see Costs of Medical Care**Edema**

Olanzapine-associated bilateral pedal edema [letter]. Christensen, Aug 972

Education

Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. Colom, Sept 1101–1105

Eicosapentaenoic Acid

Evidence that eicosapentaenoic acid is effective in treating autism [letter]. Johnson, July 848–849

Elderly

Aggression in the elderly. Brodaty, Suppl 4, 36–43
 Anxiety symptoms and quality of life in middle-aged and older outpatients with schizophrenia and schizoaffective disorder. Wetherell, Dec 1476–1482

Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. Lavretsky, Dec 1410–1414

Efficacy of controlled-release paroxetine in the treatment of late-life depression. Rapaport, Sept 1065–1074

Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report [letter]. Detweiler, July 851–852

Physical symptoms of depression: unmet needs in special populations. Stewart, Suppl 7, 12–16

Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. Oslin, Aug 875–882

Role of executive function in late-life depression. Alexopoulos, Suppl 14, 18–23

Sexual satisfaction and risk of disability in older women. Onder, Oct 1177–1182

Treatment of agitation in bipolar disorder across the life cycle. Alderfer, Suppl 4, 3–9

Use of atypical antipsychotics in nursing homes. Liperoti, Sept 1106–1112

Electroconvulsive Therapy

Dilemma of unmodified electroconvulsive therapy [commentary]. Andrade, Oct 1147–1152

Electroconvulsive therapy update: recognizing and treating psychotic depression [editorial]. Fink, Mar 232–234

Long-term follow-up of magnetic resonance–detectable choline signal changes in the hippocampus of patients treated with electroconvulsive therapy. Obergriesser, July 775–780

Pretreatment with ibuprofen to prevent electroconvulsive therapy–induced headache. Leung, May 551–553

E-mail

Suggested guidelines for e-mail communication in psychiatric practice. Silk, July 799–806

Epilepsy

Case report of hypomania following vagus nerve stimulation for refractory epilepsy [letter]. Klein, Apr 485–486

Newer anticonvulsants: dosing strategies and cognition in treating patients with mood disorders and epilepsy. Meador, Suppl 8, 30–34

Erectile Dysfunction

Aging male: androgens, erectile dysfunction, and depression. Seidman, Suppl 10, 31–37

Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation. Labbate, Suppl 10, 11–19

Depression: links with ischemic heart disease and erectile dysfunction. Roose, Suppl 10, 26–30

Introduction. Erectile dysfunction and comorbid depression: prevalence, treatment strategies, and associated medical conditions. Nurnberg, Suppl 10, 3–4

Prevalence of antidepressant-associated erectile dysfunction. Rosen, Suppl 10, 5–10

Sildenafil citrate for the management of antidepressant-associated erectile dysfunction. Nurnberg, Suppl 10, 20–25

Escitalopram

Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. Stahl, Nov 1322–1327

Estrogen

Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. Soares, Apr 473–479

Estrogen administration does not reduce the rate of recurrence of affective psychosis after childbirth. Kumar, Feb 112–118

Ethnicity

Ethnic differences in use of antipsychotic medication among Texas Medicaid clients with schizophrenia. Opolka, June 635–639

Ethnicity and diagnosis in patients with affective disorders. Strakowski, July 747–754

Executive Dysfunction

Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. Stahl, Suppl 14, 6–17

Differential diagnosis of fatigue and executive dysfunction in primary care. Lieberman, Suppl 14, 40–43

Fatigue and executive dysfunction in the primary care setting [Primary Care commentary]. Culpepper, Suppl 14, 5

Introduction: optimizing wakefulness in patients with fatigue and executive dysfunction. Stahl, Suppl 14, 3–4

Role of executive function in ADHD. Swanson, Suppl 14, 35–39

Role of executive function in late-life depression. Alexopoulos, Suppl 14, 18–23

Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. Fava M, Suppl 14, 30–34

Exercise

Aerobic endurance exercise improves executive functions in depressed patients. Kubesch, Sept 1005–1012

Expert Consensus Guideline Series

Optimizing Pharmacologic Treatment of Psychotic Disorders. Suppl 12, 1–100

Extrapyramidal Syndrome

Integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. Carlson, Aug 898–906

Family Therapy

Integrated family and individual therapy for bipolar disorder: results of a treatment development study. Miklowitz, Feb 182–191

Fatigue

Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. DeBattista, Sept 1057–1064

- Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. Stahl, Suppl 14, 6–17
- Differential diagnosis of fatigue and executive dysfunction in primary care. Lieberman, Suppl 14, 40–43
- Effectiveness of citalopram for idiopathic chronic fatigue. Hartz, Aug 927–935
- Fatigue and executive dysfunction in the primary care setting [Primary Care commentary]. Culpepper, Suppl 14, 5
- Introduction: optimizing wakefulness in patients with fatigue and executive dysfunction. Stahl, Suppl 14, 3–4
- Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. Fava M, Suppl 14, 30–34
- Fluoxetine**
- Citalopram treatment of fluoxetine-intolerant depressed patients. Calabrese, May 562–567
- Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. Winokur, Oct 1224–1229
- Double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. Hong, Aug 921–926
- Double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Barbosa, Apr 403–407
- Effect of bupropion on sexual dysfunction induced by fluoxetine: a case report of hypersexuality [letter]. Chollet, Oct 1268–1269
- Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report [letter]. Detweiler, July 851–852
- Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. Corya, Nov 1349–1356
- Fluvoxamine**
- Double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. Hollander E, June 640–647
- Formularies**
- Case for Physician Choice: Implications for Restricted Formularies. Suppl 17, 1–40
- Impact of formularies on clinical innovation. Goodwin, Suppl 17, 11–14
- Weighing the evidence: trends in managed care formulary decision making. de Lissovoy, Suppl 17, 29–32
- Fosphenytoin**
- Intravenous fosphenytoin in acute mania. Applebaum, Apr 408–409
- Gamma-Aminobutyric Acid**
- GABA systems, benzodiazepines, and substance dependence. Malcolm, Suppl 3, 36–40
- Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders. Chang, Suppl 3, 7–14
- New molecular targets for antianxiety interventions. Gorman, Suppl 3, 28–35
- Nonhuman primate studies of fear, anxiety, and temperament and the role of benzodiazepine receptors and GABA systems. Kalin, Suppl 3, 41–44
- Role of GABA in anxiety disorders. Lydiard, Suppl 3, 21–27
- Role of GABA in neuropsychiatric disorders: a review of GABA agents. Suppl 3, 1–47
- Gender**
- Do antidepressants induce rapid cycling? a gender-specific association. Yildiz, July 814–818
- Gender differences in pathological gambling. Ibáñez, Mar 295–301
- Generalized Anxiety Disorder**
- Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. Stocchi, Mar 250–258
- Hydroxyzine for generalized anxiety disorder [letter]. Sagduyu, Mar 343
- Randomized, double-blind, placebo-controlled study of classical homeopathy in generalized anxiety disorder. Bonne, Mar 282–287
- Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. Rosenthal, Oct 1245–1249
- Treating generalized anxiety disorder. Gorman, Suppl 2, 24–29
- Genetics**
- Deconstructing psychiatric disorders, pt 1: genotypes, symptom phenotypes, and endophenotypes [BRAINSTORMS]. Stahl, Sept 982–983
- Gepirone**
- Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. Feiger, Mar 243–249
- Geriatric Psychiatry see Elderly**
- Government**
- Government perspective [commentary]. Parks, Suppl 17, 37–38
- Gynecomastia**
- Case of gynecomastia during paroxetine therapy [letter]. Damsa, Aug 971
- Habit Reversal**
- Evaluating the efficacy of habit reversal: comparison with a placebo control. Twohig, Jan 40–48
- Hair Pulling see Trichotillomania**
- Hallucinations**
- Two cases of quetiapine augmentation for donepezil-refractory visual hallucinations in dementia with Lewy bodies [letter]. Terao, Dec 1520–1521
- Haloperidol**
- Effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. Spivak, July 755–760
- Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. Oosthuizen, Sept 1075–1080
- Headache**
- Pretreatment with ibuprofen to prevent electroconvulsive therapy-induced headache. Leung, May 551–553
- Heart Disease**
- Depression: links with ischemic heart disease and erectile dysfunction. Roose, Suppl 10, 26–30
- Hepatitis**
- Critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. Weinrieb, Dec 1502–1510
- Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C-seropositive state hospital patients: results from Oregon State Hospital. Meyer, May 540–545
- Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. Kraus, June 708–714
- Herbal Preparations**
- Acute liver failure after administration of the herbal tranquilizer kava-kava (*Piper methysticum*) [letter]. Brauer, Feb 216–218
- HIV**
- Open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder. Carvalhal, Apr 421–424
- Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C-seropositive state hospital patients: results from Oregon State Hospital. Meyer, May 540–545
- Homeopathy**
- Randomized, double-blind, placebo-controlled study of classical homeopathy in generalized anxiety disorder. Bonne, Mar 282–287
- Hormones**
- Aging male: androgens, erectile dysfunction, and depression. Seidman, Suppl 10, 31–37
- Human Immunodeficiency Virus see HIV**
- Hydroxyzine**
- Hydroxyzine for generalized anxiety disorder [letter]. Sagduyu, Mar 343
- Hyperglycemia**
- Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. Sernyak, May 605–608
- Hypnotics**
- Co-use of donepezil and hypnotics among Alzheimer's disease patients living in the community. Stahl, Apr 466–472
- Hypomania**
- Case report of hypomania following vagus nerve stimulation for refractory epilepsy [letter]. Klein, Apr 485–486
- Ibuprofen**
- Pretreatment with ibuprofen to prevent electroconvulsive therapy-induced headache. Leung, May 551–553
- Imipramine**
- Chronic depression and comorbid personality disorders: response to sertraline versus imipramine. Russell, May 554–561
- Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. Lepola, June 654–662
- Impulsivity**
- Impulsive aggressive behavior: open-label treatment with citalopram. Reist, Jan 81–85
- Incontinence**
- Case report of olanzapine-induced fecal incontinence [letter]. Mendhekar, Mar 339

India

Psychometric evaluation of the Alcohol Use Disorders Identification Test and short Drug Abuse Screening Test with psychiatric patients in India. Carey KB, July 767–774

Infants

Pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. Stowe, Jan 73–80

Weight gain in breastfed infants of mothers taking antidepressant medications. Hendrick, Apr 410–412

Insomnia

Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. Winokur, Oct 1224–1229

Insulin

Olanzapine induces insulin resistance: results from a prospective study. Ebenbichler, Dec 1436–1439

Intelligence

Maudsley Bipolar Disorder Project: the effect of medication, family history, and duration of illness on IQ and memory in bipolar I disorder. Donaldson, Jan 86–93

Interferon

Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. Kraus, June 708–714

Internet

Internet pharmacy prescription and phentermine overdose [letter]. Takeshita, Feb 215

Italy

Cost and outcome implications of using typical and atypical antipsychotics in ordinary practice in Italy. Percudani, Nov 1293–1299

Journal of Clinical Psychiatry

On-line manuscript submission and peer review. Jan 6–7

Happy New Year! [editorial] Gelenberg, Jan 8–11

Kava-Kava

Acute liver failure after administration of the herbal tranquilizer Kava-Kava (*Piper methysticum*) [letter]. Brauer, Feb 216–218

Lamotrigine

Double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Barbosa, Apr 403–407

Lamotrigine in patients with bipolar disorder and cocaine dependence. Brown ES, Feb 197–201

Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Calabrese, Sept 1013–1024

Leuprolide

Treatment of leuprolide-induced depression with intramuscular testosterone: a case report [letter]. Freeman, Mar 341–343

Levetiracetam

Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. Grunze, July 781–784

LHRH Agonists

Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing

hormone: a systematic review. Briken, Aug 890–897

Life Chart Method

Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH Life Chart Method. Post, June 680–690

Light Therapy see Phototherapy**Linezolid**

Linezolid, a monoamine oxidase inhibiting antibiotic, and antidepressants [letter]. Aga, May 609–610

Lipids

Effects of mirtazapine on plasma lipid profiles in healthy subjects. Nicholas, Aug 883–889

Lithium

Drug interactions of lithium and other antimanic/mood-stabilizing medications. Dunner, Suppl 5, 38–43

Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. Kennedy, Apr 439–444

Lithium combinations in acute and maintenance treatment of unipolar and bipolar depression. Fawcett, Suppl 5, 32–37

Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. Phelan, Nov 1328–1334

Lithium treatment and suicide risk in major affective disorders: update and new findings. Baldessarini, Suppl 5, 44–52

Placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Calabrese, Sept 1013–1024

Prophylactic efficacy of lithium versus carbamazepine in treatment-naïve bipolar patients. Hartong, Feb 144–151

Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. Goodwin, Suppl 5, 18–24

Safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. Hirschfeld, July 841–846

Use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. Gray, Suppl 5, 3–17

Liver Failure

Acute liver failure after administration of the herbal tranquilizer kava-kava (*Piper methysticum*). Brauer, Feb 216–218

Magnesium

Oral magnesium ion shortens prolonged QTc interval. Bachman, June 733–734. Correction, Aug 972

Magnetic Resonance Imaging see Brain Imaging**Managed Care**

Health care organization perspective [commentary]. Goldman, Suppl 17, 35–36

Weighing the evidence: trends in managed care formulary decision making. de Lissovoy, Suppl 17, 29–32

Mania

Divalproex versus olanzapine in mania [letter]. Vieta; Zajecka reply, Oct 1266–1267

Drug combinations for mania. Mondimore, Suppl 5, 25–31

Intravenous fosphenytoin in acute mania.

Applebaum, Apr 408–409

Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. Grunze, July 781–784

Mania associated with initiation of ziprasidone [letter]. Nolan, Mar 336

Mania from dose-related ziprasidone augmentation of an SSRI [letter]. Privitera, Nov 1393–1394

1-Year follow-up of patients treated with risperidone and topiramate for a manic episode. Vieta, July 834–839

Maudsley Bipolar Disorder Project

Maudsley Bipolar Disorder Project: the effect of medication, family history, and duration of illness on IQ and memory in bipolar I disorder. Donaldson, Jan 86–93

Medicaid

Unintended outcomes of medicaid drug cost-containment policies on the chronically mentally ill. Soumerai, Suppl 17, 19–22

Melancholia

Enlargement of brain cerebrospinal fluid spaces as a predictor of poor clinical outcome in melancholia. Cardoner, June 691–697

Memory

Maudsley Bipolar Disorder Project: the effect of medication, family history, and duration of illness on IQ and memory in bipolar I disorder. Donaldson, Jan 86–93

Men

Hostility during admission interview as a short-term predictor of aggression in acute psychiatric male inpatients. Troisi, Dec 1460–1464

Increased cholesterol levels during paroxetine administration in healthy men. Lara, Dec 1455–1459

Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? Kanayama, Feb 156–160

Mental Retardation

Possible antidepressant-associated activation of mania and psychosis in the mentally retarded: four case reports [letter]. Sahay, Apr 481–482

Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. Cohen, Jan 60–62

Metabolic Syndrome

Metabolic syndrome in patients with schizophrenia. Heiskanen, May 575–579

Metabolism

Olanzapine elevation of serum creatine kinase [letter]. Martí-Bonmatí, Apr 483–484

Olanzapine induces insulin resistance: results from a prospective study. Ebenbichler, Dec 1436–1439

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Atmaca, May 598–604

Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine [letter]. Kelly DL, Sept 1133–1134

Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. Cohen, Jan 60–62

Methylphenidate

- Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. Lavretsky, Dec 1410–1414
- Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. Kollins, Suppl 11, 14–18
- Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. Gothelf, Oct 1163–1169

Mirtazapine

- Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. Winokur, Oct 1224–1229
- Double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. Hong, Aug 921–926
- Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. Szegedi, Apr 413–420
- Effects of mirtazapine on plasma lipid profiles in healthy subjects. Nicholas, Aug 883–889

Modafinil

- Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. DeBattista, Sept 1057–1064
- Three case reports of modafinil use in treating sedation induced by antipsychotic medications [letter]. Makela, Apr 485–486

Mood

- Effects of breathing-related sleep disorders on mood disturbances in the general population. Ohayon, Oct 1195–1200
- Gender-specific considerations in the treatment of mood disorders in women across the life cycle. Cohen, Suppl 15, 18–29
- Impact of attempted suicide on the symptoms and course of mood disorders. Sakamoto, Oct 1210–1216
- Occult mood disorders in 104 consecutively presenting children referred for the treatment of attention-deficit/hyperactivity disorder in a community mental health clinic. Dilsaver, Oct 1170–1176

“Outer-directed irritability”: a distinct mood syndrome in explosive youth with a disruptive behavior disorder? Donovan, June 698–701

Mood Stabilizers

- Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. Henry, Mar 331–335
- Drug interactions of lithium and other antimanic/mood-stabilizing medications. Dunner, Suppl 5, 38–43
- Introduction: using the newer pharmacotherapeutic agents as mood stabilizers in bipolar spectrum disorders. Chengappa, Suppl 8, 3–4
- New approaches in managing bipolar depression. Keck, Suppl 1, 13–18
- Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. Goodwin, Suppl 5, 18–24

Use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. Gray, Suppl 5, 3–17

Myocardial Infarction

- Trajectories of posttraumatic stress disorder following myocardial infarction: a prospective study. Ginzburg, Oct 1217–1223

Nail Biting

- Evaluating the efficacy of habit reversal: comparison with a placebo control. Twohig, Jan 40–48

National Depressive and Manic-Depressive Association

- Perceptions and impact of bipolar disorder: how far have we really come? results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. Hirschfeld, Feb 161–174

Nausea

- Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. DeVane, Suppl 18, 14–19

Nefazodone

- Effect of nefazodone on subjective and objective sleep quality in posttraumatic stress disorder. Neylan, Apr 445–450

Negative Symptoms

- Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. Feldman, Sept 998–1004
- Improvement in negative symptoms of schizophrenia with antibodies to tumor necrosis factor- α and to interferon- γ : a case report [letter]. Skurkovich SV, June 734–735
- Negative symptoms in depressed and schizophrenic patients: how do they differ? Bottlender, Aug 954–958

Neuroimaging see Brain Imaging**Neuroreceptors**

- Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. Richelson, Suppl 13, 5–12
- Neuroreceptor mechanisms of aggression and its treatment. Swann, Suppl 4, 26–35
- Role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. Fava M, Suppl 13, 26–29

Nonsteroidal Anti-Inflammatory Drugs

- Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. Phelan, Nov 1328–1334

Nortriptyline

- Nortriptyline for treatment-resistant depression. Nierenberg, Jan 35–39
- Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. Papakostas, Nov 1357–1361

Nursing Homes

- Use of atypical antipsychotics in nursing homes. Liperoti, Sept 1106–1112

Nutrition

- Nutritional approach to bipolar disorder [letter]. Simmons; Simpson reply, Mar 338–339

Obsessive-Compulsive Disorder

- Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Hollander E, Sept 1113–1121
- Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia. Poyurovsky, Nov 1300–1307
- Double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. Hollander E, June 640–647
- How common is obsessive-compulsive disorder in a dermatology outpatient clinic? Fineberg, Feb 152–155
- Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder [letter]. Poyurovsky, May 611
- Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. Hewlett, Sept 1025–1030
- Venlafaxine in treatment-resistant obsessive-compulsive disorder. Hollander E, May 546–550. Correction, Aug 972
- Olanzapine**
- Case report of olanzapine-induced fecal incontinence [letter]. Mendhekar, Mar 339
- Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. Feldman, Sept 998–1004
- Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. Revicki, Mar 288–294
- Divalproex versus olanzapine in mania [letter]. Vieta; Zajecka reply, Oct 1266–1267
- Double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. Fontaine, June 726–730
- Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report [letter]. Detweiler, July 851–852
- High-dose olanzapine and prolactin levels. Karagianis, Oct 1192–1194
- Integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. Carlson, Aug 898–906
- Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. Corya, Nov 1349–1356
- Olanzapine-associated bilateral pedal edema [letter]. Christensen, Aug 972
- Olanzapine elevation of serum creatine kinase [letter]. Martí-Bonmati, Apr 483–484
- Olanzapine for cocaine cravings and relapse prevention [letter]. Sattar, Aug 969
- Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. Janowsky, Oct 1258–1265

Olanzapine induces insulin resistance: results from a prospective study. Ebenbichler, Dec 1436–1439

Olanzapine/risperidone and diabetes risk [letter]. Lee; Gianfrancesco reply, July 847–848

Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder [letter]. Poyurovsky, May 611

Open-label, flexible-dose study of olanzapine in the treatment of trichotillomania. Stewart, Jan 49–52

Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. Taylor, May 589–597

Safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. Hirschfeld, July 841–846

Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine [letter]. Kelly DL, Sept 1133–1134

Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. Godleski, Feb 119–122

Olfaction

Olfaction as a traumatic reminder in posttraumatic stress disorder: case reports and review. Vermetten, Feb 202–207

Ondansetron

Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. Hewlett, Sept 1025–1030

Oregon

Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C–seropositive state hospital patients: results from Oregon State Hospital. Meyer, May 540–545

Outcome

Recent Developments in Achieving Depression Remission. Suppl 13, 1–40

Outpatients

Suicide risk of discharged psychiatric patients. Ho, June 702–707

Overdose

Internet pharmacy prescription and phentermine overdose [letter]. Takeshita, Feb 215

Oxcarbazepine

Oxcarbazepine treatment of bipolar disorder. Ghaemi, Aug 943–945

Pain

Economic burden of depression with painful symptoms. Greenberg, Suppl 7, 17–23

Here today and not gone tomorrow: the curse of chronic pain and other central sensitization syndromes [BRAINSTORMS]. Stahl, Aug 863–864

Word of caution about the implied role for duloxetine in pain management [letter]. Leo, Oct 1270

Panic Disorder

Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. Stahl, Nov 1322–1327

Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. Lepola, June 654–662

Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. Roy-Byrne, Apr 383–389

Paraphilias

Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone–releasing hormone: a systematic review. Briken, Aug 890–897

Paresthesia

Serotonin reuptake inhibitors and shocklike paresthesia [letter]. de Graaf, Aug 969–971

Paroxetine

Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Hollander E, Sept 1113–1121

Case of gynecomastia during paroxetine therapy [letter]. Damsa, Aug 971

Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. Szegedi, Apr 413–420

Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. Stocchi, Mar 250–258

Efficacy of controlled-release paroxetine in the treatment of late-life depression. Rapaport, Sept 1065–1074

Increased cholesterol levels during paroxetine administration in healthy men. Lara, Dec 1455–1459

Paroxetine-induced somnambulism [letter]. Kawashima, Apr 483

Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. Rosenthal, Oct 1245–1249

Pathological Crying

Venlafaxine for pathological crying after stroke [letter]. Smith AG, June 731–732

Pathological Gambling

Factors at play in faster progression for female pathological gamblers: an exploratory analysis. Tavares, Apr 433–438

Gender differences in pathological gambling. Ibáñez, Mar 295–301

Suicide attempts among veterans seeking treatment for pathological gambling. Kausch, Sept 1031–1038

Patient Advocacy

Advocacy perspective [commentary]. Fitzpatrick, Suppl 17, 39–40

Personality Disorders

Chronic depression and comorbid personality disorders: response to sertraline versus imipramine. Russell, May 554–561

Relationship of personality disorders to treatment outcome in depressed outpatients. Mulder, Mar 259–264

Pharmacoeconomics

Case for Physician Choice: Implications for Restricted Formularies. Suppl 17, 1–40

Purchasing community perspective [commentary]. Moore MC, Suppl 17, 33–34

Pharmacokinetics

Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. DeVane, Suppl 18, 14–19

Psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. Stahl, Suppl 19, 6–12

Phentermine

Internet pharmacy prescription and phentermine overdose [letter]. Takeshita, Feb 215

Phototherapy

Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. Benedetti, June 648–653

Physical Symptoms

Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes [BRAINSTORMS]. Stahl, July 745–746

Depression with physical symptoms: treating to remission. Fava M, Suppl 7, 24–28

Economic burden of depression with painful symptoms. Greenberg, Suppl 7, 17–23

Here today and not gone tomorrow: the curse of chronic pain and other central sensitization syndromes [BRAINSTORMS]. Stahl, Aug 863–864

Physical symptoms of depression as a public health concern. Sartorius, Suppl 7, 3–4

Physical symptoms of depression: unmet needs. Greden, Suppl 7, 5–11

Physical symptoms of depression: unmet needs in special populations. Stewart, Suppl 7, 12–16

Physician-Patient Relations

Suggested guidelines for e-mail communication in psychiatric practice. Silk, July 799–806

Piroxicam

Carbamazepine treatment of adverse psychiatric effects after treatment with the nonsteroidal anti-inflammatory drug piroxicam [letter]. Eser, July 852–854

Placebo Control

Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. Hummer, Mar 277–281

Polydipsia

Adjunctive quetiapine treatment of the polydipsia, intermittent hyponatremia, and psychosis syndrome: a case report [letter]. Montgomery, Mar 339–341

Postpartum Psychosis

Estrogen administration does not reduce the rate of recurrence of affective psychosis after childbirth. Kumar, Feb 112–118

Relationship between postpartum psychosis and bipolar disorder: a review. Chaudron, Nov 1284–1292

Posttraumatic Stress Disorder

AMPA blockade may be the mechanism underlying the efficacy of topiramate in PTSD [letter]. Zullino, Feb 219–220

Effect of nefazodone on subjective and objective sleep quality in posttraumatic stress disorder. Neylan, Apr 445–450

Mental health treatment received by primary care patients with posttraumatic stress disorder. Rodriguez, Oct 1230–1236

Olfaction as a traumatic reminder in posttraumatic stress disorder: case reports and review. Vermetten, Feb 202–207

Posttraumatic stress disorder and its impact on the economic and health costs of motor vehicle accidents in South Australia. Chan, Feb 175–181

Tiagabine for posttraumatic stress disorder: a case series of 7 women. Taylor FB, Dec 1421–1425

- Trajectories of posttraumatic stress disorder following myocardial infarction: a prospective study. Ginzburg, Oct 1217–1223
- Predictors**
- Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. Roy-Byrne, Apr 383–389
- Pregnancy**
- Clozapine and pregnancy [letter]. Mendhekar, July 850
- Premenstrual Dysphoric Disorder**
- Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder. Endicott, Dec 1511–1516
- Prescriptions**
- Internet pharmacy prescription and phentermine overdose [letter]. Takeshita, Feb 215
- Priapism**
- Case of risperidone-induced priapism [letter]. Relan, Apr 482–483
- Priapism associated with risperidone: a case report [letter]. Bourgeois, Feb 218–219
- Prolonged erections associated with ziprasidone treatment: a case report [letter]. Reeves, Jan 97–98
- Successful treatment with clozapine at higher doses after clozapine-induced priapism [letter]. de Nesnera, Nov 1394–1395
- Primary Care**
- Attending to anxiety disorders in primary care. Stein, Suppl 15, 35–39
- Differential diagnosis of fatigue and executive dysfunction in primary care. Lieberman, Suppl 14, 40–43
- Difficult-to-treat depressions: a primary care perspective. Manning, Suppl 1, 24–31
- Fatigue and executive dysfunction in the primary care setting [PC commentary]. Culpepper, Suppl 14, 5
- Mental health treatment received by primary care patients with posttraumatic stress disorder. Rodriguez, Oct 1230–1236
- Role of algorithms in the detection and treatment of depression in primary care. Klinkman, Suppl 2, 19–23
- Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. Roy-Byrne, Apr 383–389
- Use of algorithms to treat anxiety in primary care. Culpepper, Suppl 2, 30–33
- Prolactin**
- High-dose olanzapine and prolactin levels. Karagianis, Oct 1192–1194
- Prolactin levels during long-term risperidone treatment in children and adolescents. Findling, Nov 1362–1369
- Psychiatric Emergency Service**
- Treating aggression in the psychiatric emergency service. Hughes, Suppl 4, 10–15
- Psychometric Tests**
- Psychometric evaluation of the alcohol use disorders identification test and short drug abuse screening test with psychiatric patients in India. Carey KB, July 767–774
- Psychopharmacology**
- Deconstructing psychiatric disorders, pt 2: an emerging, neurobiologically based therapeutic strategy for the modern psychopharmacologist [BRAINSTORMS]. Stahl, Oct 1145–1146
- Psychosis see also specific disorders**
- Adjunctive quetiapine treatment of the polydipsia, intermittent hyponatremia, and psychosis syndrome: a case report [letter]. Montgomery, Mar 339–341
- Optimizing Pharmacologic Treatment of Psychotic Disorders. Suppl 12, 1–100
- Predictors of quality of life in major psychoses: a naturalistic follow-up study. Ritsner, Mar 308–315
- Randomized controlled trial of different models of care for nursing home residents with dementia complicated by depression or psychosis. Brodaty, Jan 63–72
- Psychotherapy**
- Integrated family and individual therapy for bipolar disorder: results of a treatment development study. Miklowitz, Feb 182–191
- QTc**
- Oral magnesium ion shortens prolonged QTc interval. Bachman, June 733–734
- Oral magnesium ion shortens prolonged QTc interval [letter]. Bachman, June 733–734. Correction, Aug 972
- Quetiapine and QTc issues: a case report [letter]. Gupta S, May 612–613
- Quality of Life**
- Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. Revicki, Mar 288–294
- Predictors of quality of life in major psychoses: a naturalistic follow-up study. Ritsner, Mar 308–315
- Quetiapine**
- Adjunctive quetiapine treatment of the polydipsia, intermittent hyponatremia, and psychosis syndrome: a case report [letter]. Montgomery JH, Mar 339–341
- Effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. Velligan, May 524–531
- Prospective, open-label, flexible-dose study of quetiapine in the treatment of delirium. Sasaki, Nov 1316–1321
- Quetiapine and QTc issues: a case report [letter]. Gupta S, May 612–613
- Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine [letter]. Kelly DL, Sept 1133–1134
- Two cases of quetiapine augmentation for donepezil-refractory visual hallucinations in dementia with Lewy bodies [letter]. Terao, Dec 1520–1521
- Rabbit Syndrome**
- Clozapine-induced rabbit syndrome [letter]. Sethi, Feb 219
- Race**
- Racial differences in use of antipsychotics among patients with bipolar disorder [letter]. Szarek; Fleck reply, May 614–615
- Rapid Cycling**
- Do antidepressants induce rapid cycling? a gender-specific association. Yildiz, July 814–818
- Reboxetine**
- Case of risperidone-induced priapism [letter]. Relan, Apr 482–483
- Open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder. Carvalho, Apr 421–424
- Receptors**
- Clozapine-induced rabbit syndrome [letter]. Sethi, Feb 219
- Remission**
- Effectiveness of antidepressants: comparative remission rates. Thase, Suppl 2, 3–7
- Treating Depression and Anxiety to Remission. Suppl 15, 1–48
- Using treatment algorithms to bring patients to remission. Trivedi, Suppl 2, 8–13
- Risperidone**
- Case of risperidone-induced priapism [letter]. Relan, Apr 482–483
- Charles Bonnet Syndrome with visual hallucinations of childhood experience: successful treatment of 1 patient with risperidone [letter]. Maeda, Sept 1131–1132
- Clinical guidelines: dosing and switching strategies for long-acting risperidone. Marder, Suppl 16, 41–46
- Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. Feldman, Sept 998–1004
- Double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. Fontaine, June 726–730
- Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. Lane, Mar 316–320
- Olanzapine/risperidone and diabetes risk [letter]. Lee; Gianfrancesco reply, July 847–848
- 1-Year follow-up of patients treated with risperidone and topiramate for a manic episode. Vieta, July 834–839
- Priapism associated with risperidone: a case report [letter]. Bourgeois, Feb 218–219
- Prolactin levels during long-term risperidone treatment in children and adolescents. Findling, Nov 1362–1369
- Randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Brodaty, Feb 134–143
- Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. Sharpley, Feb 192–196
- Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. Becker D, July 761–766
- Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. Taylor DM, May 589–597
- Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. Bai, Nov 1342–1348
- Risperidone in the treatment of schizotypal personality disorder. Koenigsberg, June 628–634
- Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine [letter]. Kelly DL, Sept 1133–1134

- 3-Year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. Masi, Sept 1039–1047
- Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Fleischhacker, Oct 1250–1257
- Rofecoxib**
- Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. Phelan, Nov 1328–1334
- Schizoaffective Disorder**
- Anxiety symptoms and quality of life in middle-aged and older outpatients with schizophrenia and schizoaffective disorder. Wetherell, Dec 1476–1482
- Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. Ciapparelli, Apr 451–458
- Estrogen administration does not reduce the rate of recurrence of affective psychosis after childbirth. Kumar, Feb 112–118
- Predictors of quality of life in major psychoses: a naturalistic follow-up study. Ritsner, Mar 308–315
- Schizophrenia**
- Anxiety symptoms and quality of life in middle-aged and older outpatients with schizophrenia and schizoaffective disorder. Wetherell, Dec 1476–1482
- Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. Pigott, Sept 1048–1056
- Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. Hummer, Mar 277–281
- Attribution of somatization in schizophrenia patients: a naturalistic follow-up study. Ritsner, Nov 1370–1378
- Bipolar disorder and schizophrenia: distinct illnesses or a continuum? Möller, Suppl 6, 23–27
- Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. Ciapparelli, Apr 451–458
- Combination therapy: is clinical practice leading the way? [letter] Welch; Stahl reply, Jan 94–96
- Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia. Poyurovsky, Nov 1300–1307
- Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. Feldman, Sept 998–1004
- Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. Weiden, May 580–588
- Effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. Spivak, July 755–760
- Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. Lane, Mar 316–320
- Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia. Jaffe, Suppl 17, 3–6
- Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia. Opolka, June 635–639
- Improvement in negative symptoms of schizophrenia with antibodies to tumor necrosis factor- α and to interferon- γ : a case report [letter]. Skurkovich SV, June 734–735
- Integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. Carlson, Aug 898–906
- Metabolic syndrome in patients with schizophrenia. Heiskanen, May 575–579
- Negative symptoms in depressed and schizophrenic patients: how do they differ? Bottlender, Aug 954–958
- Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder [letter]. Poyurovsky, May 611
- Partial compliance and patient consequences in schizophrenia: our patients can do better. Keith, Nov 1308–1315
- Partial Compliance: The Need for Long-Acting Atypical Antipsychotics. Suppl 16, 1–49
- Polypharmacy in patients with schizophrenia. McCue, Sept 984–989
- Polypharmacy in schizophrenia: a fuzzy concept [letter]. Freudenreich; Stahl reply, Sept 1132–1133
- Predictors of quality of life in major psychoses: a naturalistic follow-up study. Ritsner, Mar 308–315
- Reducing the Risk for Suicide in Schizophrenia and Affective Disorders [ACADEMIC HIGHLIGHTS]. Sept 1122–1129
- Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. Becker, July 761–766
- Suicide attempts in schizophrenia: the role of command auditory hallucinations for suicide. Harkavy-Friedman, Aug 871–874
- Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. Godleski, Feb 119–122
- Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. Rush, Apr 357–369
- Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Fleischhacker, Oct 1250–1257
- Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. Sernyak, May 605–608
- Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient [letter]. Hofer, Oct 1267–1268
- Ziprasidone in Schizophrenia: From Acute Treatment to Long-Term Management. Suppl 19, 1–49
- Schizotypal Personality Disorder**
- Risperidone in the treatment of schizotypal personality disorder. Koenigsberg, June 628–634
- Sedation**
- Review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. Shale, May 500–505
- Three case reports of modafinil use in treating sedation induced by antipsychotic medications [letter]. Makela, Apr 485–486
- Selective Serotonin Reuptake Inhibitors**
- Burning mouth syndrome as a side effect of SSRIs [letter]. Levenson; Maina reply, Mar 336–338
- Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder. Endicott, Dec 1511–1516
- Critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. Weinrieb, Dec 1502–1510
- Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. Mallick, Mar 321–330
- High-dose sildenafil citrate for selective serotonin reuptake inhibitor-associated ejaculatory delay: open clinical trial. Seidman, June 721–725
- Long-term side effects of SSRIs: sexual dysfunction and weight gain. Hirschfeld, Suppl 18, 20–24
- Serotonin reuptake inhibitors and shocklike paresthesia [letter]. de Graaf, Aug 969–971
- Selegiline**
- Double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. Amsterdam, Feb 208–214
- Self-Injurious Behavior**
- Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. Janowsky, Oct 1258–1265
- Treatment of previously undiagnosed psychiatric disorders in persons with developmental disabilities decreased or eliminated self-injurious behavior. Tsiouris, Sept 1081–1090
- Sertraline**
- Chronic depression and comorbid personality disorders: response to sertraline versus imipramine. Russell, May 554–561
- Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. Liebowitz, July 785–792
- Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder [letter]. Poyurovsky, May 611
- Pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. Stowe, Jan 73–80
- Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. Oslin, Aug 875–882
- Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression. Simpson, Aug 959–965

Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. Lepola, June 654–662

Sexual Function

Erectile Dysfunction and Comorbid Depression: Prevalence, Treatment Strategies, and Associated Medical Conditions. Suppl 10, 1–37

Evaluation of sexual changes after stroke. Giaquinto, Mar 302–307

High-dose sildenafil citrate for selective serotonin reuptake inhibitor–associated ejaculatory delay: open clinical trial. Seidman, June 721–725

Long-term side effects of SSRIs: sexual dysfunction and weight gain. Hirschfeld, Suppl 18, 20–24

Sexual satisfaction and risk of disability in older women. Onder, Oct 1177–1182

Sildenafil Citrate

High-dose sildenafil citrate for selective serotonin reuptake inhibitor–associated ejaculatory delay: open clinical trial. Seidman, June 721–725

Sildenafil citrate for the management of antidepressant-associated erectile dysfunction. Nurnberg, Suppl 10, 20–25

Sleep

Effect of nefazodone on subjective and objective sleep quality in posttraumatic stress disorder. Neylan, Apr 445–450

Effects of breathing-related sleep disorders on mood disturbances in the general population. Ohayon, Oct 1195–1200

Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. Sharpley, Feb 192–196

Treatment strategies for sleep disturbance in patients with depression. Doghramji, Suppl 14, 24–29

Social Anxiety Disorder

Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. Liebowitz, July 785–792

Somatic Symptoms see Physical Symptoms Somatization

Attribution of somatization in schizophrenia patients: a naturalistic follow-up study. Ritsner, Nov 1370–1378

Somnambulism

Paroxetine-induced somnambulism [letter]. Kawashima, Apr 483

Stanley Foundation Bipolar Network

Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. Leverich, May 506–515

Steatohepatitis

Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics [letter]. Haberfellner, July 851

Steroids

Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? Kanayama, Feb 156–160

St. John's Wort

Safety of St. John's Wort (*Hypericum perforatum*) during breastfeeding. Lee A, Aug 966–968

Stimulants

Childhood stimulant treatment and risk for later substance abuse. Fischer, Suppl 11, 19–23

Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. Kollins, Suppl 11, 14–18

Does stimulant treatment lead to substance use disorders? Faraone, Suppl 11, 9–13

Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Biederman, Suppl 11, 3–8

Stroke

Evaluation of sexual changes after stroke.

Giaquinto, Mar 302–307

Venlafaxine for pathological crying after stroke [letter]. Smith AG, June 731–732

Substance Abuse

Childhood stimulant treatment and risk for later substance abuse. Fischer, Suppl 11, 19–23

Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. Kollins, Suppl 11, 14–18

Does stimulant treatment lead to substance use disorders? Faraone, Suppl 11, 9–13

GABA systems, benzodiazepines, and substance dependence. Malcolm, Suppl 3, 36–40

Lamotrigine in patients with bipolar disorder and cocaine dependence. Brown ES, Feb 197–201

Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? Kanayama, Feb 156–160

Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. Biederman, Suppl 11, 3–8

Suicide

Agitation and inpatient suicide [letter]. Sharma V; Busch reply, Dec 1517–1518

Clinical correlates of inpatient suicide. Busch, Jan 14–19

Effectiveness of close watch precautions in suicidal patients [letter]. Aldrich; Fawcett reply, Dec 1520

Effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. Spivak, July 755–760

Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. Leverich, May 506–515

Impact of attempted suicide on the symptoms and course of mood disorders. Sakamoto, Oct 1210–1216

Lithium treatment and suicide risk in major affective disorders: update and new findings. Baldessarini, Suppl 5, 44–52

Preventing inpatient suicide [commentary]. Goodwin, Jan 12–13

Reducing the risk for suicide in schizophrenia and affective disorders [ACADEMIC HIGHLIGHTS]. Sept 1122–1129

Suicidal ideation and attempts among psychiatric patients with major depressive disorder. Sokero, Sept 1094–1100

Suicide attempts among veterans seeking treatment for pathological gambling. Kausch, Sept 1031–1038

Suicide attempts in schizophrenia: the role of command auditory hallucinations for suicide. Harkavy-Friedman, Aug 871–874

Suicide risk of discharged psychiatric patients. Ho, June 702–707

Treatment of anxiety in suicidal patients [letter]. Rich; Fawcett reply, Dec 1518–1519

Tardive Dyskinesia

Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. Oosthuizen, Sept 1075–1080

Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. Bai, Nov 1342–1348

Testosterone

Treatment of leuprolide-induced depression with intramuscular testosterone: a case report [letter]. Freeman, Mar 341–343

Tetrahydrocannabinol

A9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette Syndrome: a 6-week randomized trial. Müller-Vahl, Apr 459–465

Texas

Ethnic differences in use of antipsychotic medication among Texas Medicaid clients with schizophrenia. Opolka, June 635–639

Texas Medication Algorithm Project

Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. Suppes, Apr 370–382

Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. Rush, Apr 357–369

Thromboembolism

Clozapine and venous thromboembolism: further evidence [letter]. Selten, May 609

Tiagabine

Tiagabine for posttraumatic stress disorder: a case series of 7 women. Taylor FB, Dec 1421–1425

Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. Rosenthal, Oct 1245–1249

Tics

A9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette Syndrome: a 6-week randomized trial. Müller-Vahl, Apr 459–465

Topiramate

AMPA blockade may be the mechanism underlying the efficacy of topiramate in PTSD [letter]. Zullino, Feb 219–220

1-year follow-up of patients treated with risperidone and topiramate for a manic episode. Vieta, July 834–839

Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, pt 1: improvement in binge and purge measures. Hoopes, Nov 1335–1341

Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, pt 2: improvement in psychiatric measures. Hedges, Dec 1449–1454

Two cases of alcohol craving curbed by topiramate [letter]. Komanduri, May 612

Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient [letter]. Hofer, Oct 1267–1268

Tourette Syndrome

Δ9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette Syndrome: a 6-week randomized trial. Müller-Vahl, Apr 459–465

Transcranial Magnetic Stimulation

Efficacy and safety of bilateral rTMS in medication-resistant depression [letter]. Cohen, May 613–614

High-frequency repetitive transcranial magnetic stimulation decreases cigarette smoking. Eichhammer, Aug 951–953

Treatment Outcome

Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer. Henry, Mar 331–335

Can long-term treatment with antidepressant drugs worsen the course of depression? Fava GA, Feb 123–133

Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. Mallick, Mar 321–330

Relationship of personality disorders to treatment outcome in depressed outpatients. Mulder, Mar 259–264

Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice. Cuffel, Apr 397–402

Unemployment and emergency room visits predict poor treatment outcome in primary care panic disorder. Roy-Byrne, Apr 383–389

Trichotillomania

Open-label, flexible-dose study of olanzapine in the treatment of trichotillomania. Stewart, Jan 49–52

United States

Economic burden of depression in the United States: how did it change between 1990 and 2000? Greenberg, Dec 1465–1475

Vagus Nerve Stimulation

Case report of hypomania following vagus nerve stimulation for refractory epilepsy [letter]. Klein, Apr 485–486

Valproate

Use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. Gray, Suppl 5, 3–17

Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient [letter]. Hofer, Oct 1267–1268

Velocardiofacial Syndrome

Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and

adolescents with velocardiofacial syndrome: an open-label study. Gothelf, Oct 1163–1169

Venlafaxine

Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. Mallick, Mar 321–330

Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. Oslin, Aug 875–882

Venlafaxine for pathological crying after stroke [letter]. Smith AG, June 731–732

Venlafaxine in treatment-resistant obsessive-compulsive disorder. Hollander E, May 546–550. Correction, Aug 972

Veterans

Suicide attempts among veterans seeking treatment for pathological gambling. Kausch, Sept 1031–1038

Use of antidepressants in alcohol-dependent veterans. Petrakis, Aug 865–870

Violence

Mental disorder and serious violence: the victims. Johnston. July 819–824

Review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. Shale, May 500–505

Weight

Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. Keck, Dec 1426–1435

Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. Lane, Mar 316–320

Long-term side effects of SSRIs: sexual dysfunction and weight gain. Hirschfeld, Suppl 18, 20–24

Reversal of antipsychotic-associated weight gain. O'Keefe, Aug 907–912

Safety of available agents used to treat bipolar disorder: focus on weight gain. Nemeroff, May 532–539

Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine [letter]. Kelly DL, Sept 1133–1134

Weight gain in breastfed infants of mothers taking antidepressant medications. Hendrick, Apr 410–412

Weight gain in the treatment of mood disorders. Aronne, Suppl 8, 22–29

Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. Cohen, Jan 60–62

Women

Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. Soares, Apr 473–479

Estrogen administration does not reduce the rate of recurrence of affective psychosis after childbirth. Kumar, Feb 112–118

Factors at play in faster progression for female pathological gamblers: an exploratory analysis. Tavares, Apr 433–438

Gender-specific considerations in the treatment of mood disorders in women across the life cycle. Cohen, Suppl 15, 18–29

Pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. Stowe, Jan 73–80

Physical symptoms of depression: unmet needs in special populations. Stewart, Suppl 7, 12–16

Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. Becker D, July 761–766

Safety of St. John's Wort (*Hypericum perforatum*) during breastfeeding. Lee A, Aug 966–968

Sexual satisfaction and risk of disability in older women. Onder, Oct 1177–1182

Special issues related to the treatment of depression in women. Yonkers, Suppl 18, 8–13

Weight gain in breastfed infants of mothers taking antidepressant medications. Hendrick, Apr 410–412

Ziprasidone

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. Weiden, May 580–588

Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia. Brook, Suppl 19, 13–18

Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management. Kane, Suppl 19, 3–5

Maintaining symptom control: review of ziprasidone long-term efficacy data. Schooler, Suppl 19, 26–32

Mania associated with initiation of ziprasidone [letter]. Nolan, Mar 336

Mania from dose-related ziprasidone augmentation of an SSRI [letter]. Privitera, Nov 1393–1394

Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. Kane, Suppl 19, 19–25

Prolonged erections associated with ziprasidone treatment: a case report [letter]. Reeves, Jan 97–98

Psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. Stahl, Suppl 19, 6–12

Tolerability of ziprasidone: an expanding perspective. Daniel, Suppl 19, 40–49

Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. Cohen, Jan 60–62

Ziprasidone and cognition: the evolving story. Harvey, Suppl 19, 33–39

Ziprasidone augmentation of clozapine in 11 patients [letter]. Kaye, Feb 215–216